Bempedoic Acid/Ezetimibe Combination Tablet
Corporate Commitment to Innovation and Research in Science
At ESPERION, our world-renowned team of experts are committed to Research and Development that will change the lipid management landscape. This has been the first major development program for ESPERION. You can read more about our pipeline below.

Development Timeline for Bempedoic Acid 180 mg/ezetimibe 10 mg combination tablet1,2
Bempedoic Acid/Ezetimibe
Oral, small molecule in fixed-dose combination
 
Lowering
elevated LDL-C
PHASE 1
PHASE 2
PHASE 3
FDA Approval 
Feb. 26, 2020
LDL-C=low-density lipoprotein cholesterol.
On Feb. 26, 2020, the Food and Drug Administration (FDA) provided approval for the use of bempedoic acid 180 mg/ezetimibe 10 mg combination tablet.
Get updates about ESPERION and the bempedoic acid/ezetimibe
combination tablet
References: 1. Data on file. Esperion Therapeutics, Inc. 2019. 2. A study evaluating the safety and efficacy of bempedoic acid plus ezetimibe fixed-dose combination compared to bempedoic acid, ezetimibe, and placebo in patients treated with maximally tolerated statin therapy. ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03337308. Accessed February 8, 2019.